methylphenidate + fluoxetine + risperidone

This is an unbranded **combination of three psychiatric pharmaceutical agents**: methylphenidate, fluoxetine, and risperidone. - **Methylphenidate** is a central nervous system stimulant, commonly used to treat attention-deficit hyperactivity disorder (ADHD) and narcolepsy. - **Fluoxetine** is a selective serotonin reuptake inhibitor (SSRI) antidepressant, primarily used to treat depression, anxiety disorders, and some forms of obsessive-compulsive disorder. - **Risperidone** is an atypical (second-generation) antipsychotic prescribed for schizophrenia, bipolar disorder, irritability associated with autism, and as an adjunct in severe depression. The combination is not available as a single branded or generic pharmaceutical product, but the three drugs are sometimes prescribed together, especially for children or adolescents with complex neuropsychiatric comorbidities (e.g., ADHD, depression, and mood or psychotic symptoms)[1][2][4]. Mechanistically, this combination targets **multiple neurotransmitter systems**: dopamine and norepinephrine (methylphenidate), serotonin (fluoxetine), and dopamine/serotonin (risperidone), providing a multi-modal approach to challenging neuropsychiatric disorders. There are important safety and interaction considerations, including an increased risk of movement disorders (extrapyramidal symptoms) when methylphenidate and risperidone are combined, and potential for serotonin syndrome when fluoxetine is combined with other serotonergic agents or stimulants[1]. This combination should only be prescribed and monitored by qualified clinicians.